TAK Takeda Pharmaceutical Company L
$20.27▼ -0.78%
Healthcare
Other
After hours
$20.29▲ +0.10%
Oct 27, 4:05 PM ET
Volume 2.15M
Avg Volume (10D) 3.02M
Key Metrics & Fundamentals
Market Cap
$64.75B
P/E Ratio
42.2
Div Yield
3.02%
52W Range
12.99 - 20.55
% vs 50 MA
8.35%
% vs 200 MA
15.91%
RSI-14
68.4
MACD Histogram
+0.1300
Beta (1Y vs SPY)
0.12
Free Cash Flow
$127.60M
Gross Rev
$1.22T
Gross Profit
$813.22B
EBITDA
$337.49B
COGS
$406.68B
Operating Exp
$611.81B
Operating Income
$201.42B
EBIT
$201.42B
Pretax Income
$162.72B
Net Income
$113.20B
EPS (Diluted)
35.27
Price & Volume History
Loading chart…
Recent News
2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
PR Newswire · Oct 25, 2026 8:00 PM ET
Takeda Cancer Drug Extends Survival in Phase 3 Gastric Cancer Trial
MT Newswires · Oct 23, 2026 8:11 AM ET
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
Business Wire · Oct 23, 2026 7:30 AM ET
Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage
MarketBeat · Oct 22, 2026 7:04 PM ET
Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading
MT Newswires · Oct 22, 2026 10:39 AM ET
Stephen K. Brannan, MD, and John D. Young Appointed to Slate Medicines Board of Directors
Exec Edge · Oct 20, 2026 6:03 PM ET
Disease Clearance Data Might Change The Case For Investing In Takeda (TSE:4502)
Simply Wall St. · Oct 20, 2026 12:09 PM ET
Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
MT Newswires · Oct 20, 2026 10:40 AM ET
Merck KGaA bets on RNAi with $1.3B Silence buyout
BioPharma Dive · Oct 19, 2026 9:59 AM ET
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
Business Wire · Oct 19, 2026 5:30 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See TAK's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.